Ethnobotanical significance of medicinal plants: Beta-amyloid and tau aggregation inhibitors against Alzheimer's disease

被引:6
|
作者
Ganapathy, A. Anand [1 ,2 ]
Haripriya, Vijayakumari M. M. [1 ,2 ]
Acharya, Niyati [3 ]
Somappa, Sasidhar B. B. [1 ,2 ]
Kumaran, Alaganandam [1 ,2 ]
机构
[1] CSIR Natl Inst Interdisciplinary Sci & Technol, Div Chem Sci & Technol, Thiruvananthapuram 695019, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad, India
[3] Nirma Univ, Inst Pharm, Ahmadabad, Gujarat, India
关键词
Alzheimer's disease; beta-amyloid; ethnobotany; phytochemistry; tau; LONICERA JAPONICA THUNB; CLEAVING ENZYME 1; IN-VITRO; PROTEIN HYPERPHOSPHORYLATION; SCUTELLARIA-BAICALENSIS; FIBRIL FORMATION; GINSENOSIDE RD; GINKGO-BILOBA; PC12; CELLS; EXTRACT;
D O I
10.1002/jbt.23339
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among the various neurodegenerative disorders, Alzheimer's disease (AD) is identified as one of primary causes of dementia in the elderly, which progresses slowly leading to cognitive decline and ability to function independently. Although various pathological mechanisms have been proposed, the exact mechanism is not yet elucidated. Numerous processes such as old age, mitochondrial dysfunction, and genetics lead to the aggregation of beta-amyloid (A beta) as amyloid plaques and tau proteins as neurofibrillary tangles in the neurons leading to their death and destruction, finally leading to AD. The current treatment measures can only temporarily improve the symptoms, slowing cognitive decline without any effect on AD pathology for better therapeutic effect. Furthermore, the high failure rates of a number of drugs during clinical trials due to their side effects has led the researchers to focus on alternative sources for drug development. As natural ingredients were considered the primary line of treatment in the olden days, and as several medicinal plant products are also proven as effective AD targets, it will be wise to investigate those with significant ethnobotanical value as potential neuroprotectives, nootropics or memory boosters. Throughout the study, propanoids, glycosides, iridoids, carotenoids and flavonoids that show potential anti-inflammatory, antioxidant, and anti-cholinesterase were also found to be inhibitors of A beta and tau aggregation, where Saikosaponin C, Fisetin, and Morin can act as dual inhibitors. The review provides an insight in the need for proper and complete scientific evaluation of these ethnobotanically useful medicinal plants to be identified as potential leads in AD therapy.
引用
收藏
页数:30
相关论文
共 50 条
  • [41] The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease
    Spires-Jones, Tara L.
    Hyman, Bradley T.
    NEURON, 2014, 82 (04) : 756 - 771
  • [42] Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease
    Youm, Jung Won
    Jeon, Jae Heung
    Kim, Hee
    Kim, Young Ho
    Ko, Kisung
    Joung, Hyouk
    Kim, HyunSoon
    BIOTECHNOLOGY LETTERS, 2008, 30 (10) : 1839 - 1845
  • [43] Rapid multiplexed detection of beta-amyloid and total-tau as biomarkers for Alzheimer's disease in cerebrospinal fluid
    Song, Chao
    Deng, Pan
    Que, Long
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018, 14 (06) : 1845 - 1852
  • [44] Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease
    Moosavi, Behrooz
    Mousavi, Bibimaryam
    Macreadie, Ian G.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 47 (01) : 9 - 16
  • [45] AGGREGATION STATE AND NEUROTOXIC PROPERTIES OF ALZHEIMER BETA-AMYLOID PEPTIDE
    HOWLETT, DR
    JENNINGS, KH
    LEE, DC
    CLARK, MSG
    BROWN, F
    WETZEL, R
    WOOD, SJ
    CAMILLERI, P
    ROBERTS, GW
    NEURODEGENERATION, 1995, 4 (01): : 23 - 32
  • [46] In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer's Disease Treatment
    Job, Nisha
    Thimmakondu, Venkatesan S. S.
    Thirumoorthy, Krishnan
    MOLECULES, 2023, 28 (03):
  • [47] Cerebrospinal Tau, Phospho-Tau, and Beta-Amyloid and Neuropsychological Functions in Parkinson's Disease
    Compta, Yaroslau
    Marti, Maria J.
    Ibarretxe-Bilbao, Naroa
    Junque, Carme
    Valldeoriola, Francesc
    Munoz, Esteban
    Ezquerra, Mario
    Rios, Jose
    Tolosa, Eduardo
    MOVEMENT DISORDERS, 2009, 24 (15) : 2203 - 2210
  • [48] The subcellular neuropathology of Alzheimer's beta-amyloid
    Gouras, GK
    Li, F
    Takahashi, RH
    NEUROLOGY, 2002, 58 (07) : A364 - A364
  • [49] CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease
    Samuels, SC
    Silverman, JM
    Marin, DB
    Peskind, ER
    Younki, SG
    Greenberg, DA
    Schnur, E
    Santoro, J
    Davis, KL
    NEUROLOGY, 1999, 52 (03) : 547 - 551
  • [50] Investigating the effects of beta-amyloid on hippocampal signalling in Alzheimer's disease
    Julia M Warburton
    Daniel J Whitcomb
    Krasimira Tsaneva-Atanasova
    Kei Cho
    BMC Neuroscience, 16 (Suppl 1)